<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36064599</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.</ArticleTitle><Pagination><StartPage>1813</StartPage><EndPage>1822</EndPage><MedlinePgn>1813-1822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-022-01956-3</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to paralysis and death typically within 3-5 years of diagnosis. Dysfunctional astrocytes may contribute to disease and glial cell line-derived neurotrophic factor (GDNF) can be protective. Here we show that human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models. CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord of 18 ALS participants in a phase 1/2a study (NCT02943850). The primary endpoint of safety at 1 year was met, with no negative effect of the transplant on motor function in the treated leg compared with the untreated leg. Tissue analysis of 13 participants who died of disease progression showed graft survival and GDNF production. Benign neuromas near delivery sites were common incidental findings at post-mortem. This study shows that one administration of engineered neural progenitors can provide new support cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Johnson</LastName><ForeName>J Patrick</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Spine Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Avalos</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allred</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svendsen</LastName><ForeName>Soshana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gowing</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujifilm Cellular Dynamics, Inc., Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roxas</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9546-1472</Identifier><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donahue</LastName><ForeName>Becky</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>Sheryl</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawless</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelley</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fujifilm Cellular Dynamics, Inc., Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Koral</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prina</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kendra-Romito</LastName><ForeName>Tami</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stokes</LastName><ForeName>Haniah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manoukian</LastName><ForeName>Vicki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muthukumaran</LastName><ForeName>Abirami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#xf1;uelos</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godoy</LastName><ForeName>Marlesa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7012-1612</Identifier><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresee</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drazin</LastName><ForeName>Doniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Providence Regional Medical Center Everett, Everett, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naruse</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Harish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, SUNY-Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vo</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elsayegh</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tourtellotte</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maya</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burford</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3526-1852</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Chirag G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svendsen</LastName><ForeName>Clive N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0001-8696-3446</Identifier><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Clive.svendsen@cshs.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02943850</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K26 OD010945</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K26 RR026099</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095894</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2022 Sep;28(9):1751-1752</RefSource><PMID Version="1">36097225</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2022 Nov;28(11):897-899</RefSource><PMID Version="1">36182630</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="Y">Neural Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Cedars-Sinai owns the patent application related to the frame and cannula tested in this study. Pablo Avalos and Doniel Drazin are named on the patent application.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36064599</ArticleId><ArticleId IdType="pmc">PMC9499868</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01956-3</ArticleId><ArticleId IdType="pii">10.1038/s41591-022-01956-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms MB, Baloh RH. Clinical neurogenetics: amyotrophic lateral sclerosis. Neurol. Clin. 2013;31:929&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3815699</ArticleId><ArticleId IdType="pubmed">24176417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z-W, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Commun. 2015;6:6626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH, Glass JD, Svendsen CN. Stem cell transplantation for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018;31:655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080719</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp. Neurol. 2010;223:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682989</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology. 2019;93:e2294&#x2013;e2305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, et al. Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl. Med. 2019;8:887&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708070</ArticleId><ArticleId IdType="pubmed">31104357</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87:392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Long-term phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 2018;5:730&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008;11:1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656686</ArticleId><ArticleId IdType="pubmed">18931666</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen CN, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson&#x2019;s disease. Exp. Neurol. 1997;148:135&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">9398456</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SM, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 2005;16:509&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">15871682</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrstock S, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 2006;13:379&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">16355116</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride JL, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington&#x2019;s disease. J. Comp. Neurol. 2004;475:211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211462</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrstock S, et al. Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant. 2008;17:753&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650839</ArticleId><ArticleId IdType="pubmed">19044202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostenfeld T, et al. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp. Neurol. 2000;164:215&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10877932</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres RH, et al. Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain. 2011;134:1777&#x2013;1789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102243</ArticleId><ArticleId IdType="pubmed">21616972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez J, et al. Preclinical validation of multilevel intraparenchymal stem cell therapy in the porcine spinal cord. Neurosurgery. 2015;77:604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">26134596</ArticleId></ArticleIdList></Reference><Reference><Citation>Emborg ME, et al. GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant. 2008;17:383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">18522241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. Long-term vision rescue by human neural progenitors in a rat model of photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49:3201&#x2013;3206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055787</ArticleId><ArticleId IdType="pubmed">18579765</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE. 2007;2:e689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, et al. Glial cell line-derived neurotrophic factor-secreting human neural progenitors show long-term survival, maturation into astrocytes, and no tumor formation following transplantation into the spinal cord of immunocompromised rats. Neuroreport. 2014;25:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969154</ArticleId><ArticleId IdType="pubmed">24284956</ArticleId></ArticleIdList></Reference><Reference><Citation>Das MM, et al. Human neural progenitors differentiate into astrocytes and protect motor neurons in aging rats. Exp. Neurol. 2016;280:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">27032721</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, et al. Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis. Stem Cells. 2018;36:1122&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">29656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, et al. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS ONE. 2011;6:e25968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187829</ArticleId><ArticleId IdType="pubmed">21998733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">8493557</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson CE, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266:1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">7973664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003;9:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">12669033</ArticleId></ArticleIdList></Reference><Reference><Citation>Slevin JT, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005;102:216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">15739547</ArticleId></ArticleIdList></Reference><Reference><Citation>Alisky JM, Davidson BL. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum. Gene Ther. 2000;11:2315&#x2013;2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">11096437</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelley, B. C., Gowing, G. &amp; Svendsen, C. N. A cGMP-applicable expansion method for aggregates of human neural stem and progenitor cells derived from pluripotent stem cells or fetal brain tissue. J. Vis. Exp.88, 51219 (2014); 10.3791/51219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195512</ArticleId><ArticleId IdType="pubmed">24962813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovland DN, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007;35:676&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">17763282</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler J, et al. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol. 1997;41:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005869</ArticleId></ArticleIdList></Reference><Reference><Citation>Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp. Neurol. 1997;145:24&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushton DJ, Andres PL, Allred P, Baloh RH, Svendsen CN. Patients with ALS show highly correlated progression rates in left and right limb muscles. Neurology. 2017;89:196&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501935</ArticleId><ArticleId IdType="pubmed">28600459</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradas J, et al. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology. 1993;43:751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">8469335</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, et al. Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects. Gene Ther. 2017;24:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404206</ArticleId><ArticleId IdType="pubmed">28276446</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas Cheng H. Spinal cord mechanisms of chronic pain and clinical implications. Curr. Pain. Headache Rep. 2010;14:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155807</ArticleId><ArticleId IdType="pubmed">20461476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez I, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson&#x2019;s disease. Brain. 2005;128:1498&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610438</ArticleId><ArticleId IdType="pubmed">15872020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser RA, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 1999;56:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson&#x2019;s disease. N. Engl. J. Med. 1995;332:1118&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">7700284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Fetal grafting for Parkinson&#x2019;s disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 1997;6:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">9171154</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, et al. Nerve injury induces glial cell line-derived neurotrophic factor (GDNF) expression in Schwann cells through purinergic signaling and the PKC-PKD pathway. Glia. 2013;61:1029&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165612</ArticleId><ArticleId IdType="pubmed">23553603</ArticleId></ArticleIdList></Reference><Reference><Citation>Reith W, Hau&#xdf;mann A. Importance of Virchow&#x2013;Robin spaces. Radiologie. 2018;58:142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">29374313</ArticleId></ArticleIdList></Reference><Reference><Citation>Imitola J, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl Acad. Sci. USA. 2004;101:18117&#x2013;18122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC536055</ArticleId><ArticleId IdType="pubmed">15608062</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NL, et al. Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am. J. Respir. Crit. Care Med. 2013;187:535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733409</ArticleId><ArticleId IdType="pubmed">23220913</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen CN, et al. A new method for the rapid and long term growth of human neural precursor cells. J. Neurosci. Methods. 1998;85:141&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874150</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, et al. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012;45:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190312</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56:710&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">28120413</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre&#x2013;post designs. Sankhy&#x101; Ind. J. Stat. Ser. B (1960&#x2013;2002) 2000;62:134&#x2013;148.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>